National Comprehensive Cancer Network-Pharmaceuticals & Healthcare-Deals and Alliances Profile

National Comprehensive Cancer Network-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH195218D
  • |
  • Pages: 39
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

National Comprehensive Cancer Network (NCCN) is a contract research organization that offers clinical services. The organization provides research and medical information to help patients and health professionals related to cancer care. It provides subscriptions and products such as, NCCN flash updates, NCCN drugs and biologic compendium, NCCN chemotherapy order templates, NCCN trends and NCCN academy video modules, among others. The organization research areas include oncology pre clinical, translation and clinical research. It holds projects related to oncology research program and oncology outcomes database. The organization offers services to patients, clinicians and health care decision-makers. NCCN is headquartered in Fort Washington, Pennsylvania, the US.

National Comprehensive Cancer Network-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 13

BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14

Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 14

Bristol-Myers Squibb Enters into Research Agreement with NCCN 15

A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 16

Juno Therapeutics Enters into Research Agreement with FHCRC 17

Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 18

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 19

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 20

Licensing Agreements 21

Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 21

Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 22

Juno Therapeutics Enters into Licensing Agreement with FHCRC 23

Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 24

National Comprehensive Cancer Network-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Government and Public Interest 30

Sep 26, 2016: NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms 30

Aug 29, 2016: New NCCN Imaging Appropriate Use Criteria Published for Eight Cancer Types 31

Apr 11, 2016: Helsinn Supports the Development of NCCN Guidelines For Patients on Nausea and Vomiting, with a Sponsorship Grant 32

Mar 21, 2016: Interventions Required to Reduce Non-Cancer-Related Hospitalizations for Elderly Men after Prostate Cancer Diagnosis, Study Finds 33

Feb 22, 2016: NCCN, in Collaboration With Pfizer, Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives 34

Feb 12, 2016: New NCCN Guidelines Include Evidence Blocks to Illustrate Value in Breast, Colon, Kidney, and Rectal Cancers 35

Product News 36

Jan 27, 2016: Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care With Big Data 36

Other Significant Developments 37

Oct 04, 2016: New NCCN Patient Resources Assist Decision-Making for People With Stomach Cancer 37

Mar 03, 2016: NCCN Publishes New Patient Education Resources for Patients with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma-a Rare, Yet Curable, Blood Cancer 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39

List of Figures

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Key Facts 1

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

National Comprehensive Cancer Network, Deals By Therapy Area, 2011 to YTD 2017 9

National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10

National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 13

BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14

Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 14

Bristol-Myers Squibb Enters into Research Agreement with NCCN 15

A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 16

Juno Therapeutics Enters into Research Agreement with FHCRC 17

Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 18

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 19

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 20

Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 21

Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 22

Juno Therapeutics Enters into Licensing Agreement with FHCRC 23

Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 24

National Comprehensive Cancer Network, Key Competitors 26

National Comprehensive Cancer Network, Key Employees 27

National Comprehensive Cancer Network, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

National Comprehensive Cancer Network, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com